- Home
- GSBC vs LBRX Comparison
GSBC vs LBRX Comparison
Compare GSBC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSBC | LBRX |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.5M | 563.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | GSBC | LBRX |
|---|---|---|
| Price | $61.60 | $22.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $59.50 | $49.00 |
| AVG Volume (30 Days) | 55.9K | ★ 508.7K |
| Earning Date | 01-20-2026 | 02-15-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 18.31 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $228,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.26 | ★ N/A |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $47.58 | $13.36 |
| 52 Week High | $66.59 | $23.15 |
Technical Indicators
Market Signals| Indicator | GSBC | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | N/A |
| Support Level | $65.08 | N/A |
| Resistance Level | $63.55 | N/A |
| Average True Range (ATR) | 1.10 | 0.00 |
| MACD | -0.55 | 0.00 |
| Stochastic Oscillator | 6.07 | 0.00 |
Price Performance
Historical ComparisonAbout GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.